E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

Nature Biotechnology

Volumn 21, Issue 11, 2003, Pages 1328-1335

  Wang, Yaohe ^a   Hallden, Gunnel ^a   Hill, Richard ^a   Anand, Arthi ^a   Liu, Ta Chiang ^a   Francis, Jennelle ^a   Brooks, Gabriel ^a   Lemoine, Nick ^a   Kirn, David ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGY; PATIENT MONITORING; VIRUSES;

GENE EFFECTS;

GENES;

ADENOVIRUS VECTOR; GAMMA INTERFERON; ONCOLYTIC VIRUS; TUMOR NECROSIS FACTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CARCINOMA CELL; CELL INFILTRATION; CELL STRAIN; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG DESIGN; DRUG SCREENING; EMBRYO; GENE EXPRESSION; GENE THERAPY; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOREGULATION; MACROPHAGE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS E3 GENE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E3 PROTEINS; ANIMALS; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; IMMUNOCOMPETENCE; MICE; MICE, NUDE; RECOMBINANT PROTEINS; VIRUS ACTIVATION;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; MUS MUSCULUS;

EID: 0242290921     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt887     Document Type: Article

References (52)

1. Kirn, D., Martuza, R.L. & Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7, 781-787 (2001).
2. Kirn, D. Replication-selective micro-organisms: fighting cancer with targeted germ warfare. J. Clin. Invest. 105, 836-838 (2000).
3. Kirn, D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19, 6660-6668 (2000).
4. Bischoff, J.R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science 274, 373-376 (1996).
5. Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nat. Med. 3, 639-645 (1997).
6. Yu, D., Sakamoto, G. & Henderson, D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59, 1498-1504 (1999).
7. Yu, D., Chen, Y., Seng, M., Dilley, J. & Henderson, D.R. The addition of adenovirus region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200-4203 (1999).
8. Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nat. Med. 6, 1134-1139 (2000).
9. Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D. & Kim, J.H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy [see comments]. Hum. Gene Ther. 9, 1323-1333 (1998).
10. Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12 (2000).
11. Kurihara, T., Brough, D.E., Kovesdi, I. & Kufe, D.W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106, 763-771 (2000).
12. Johnson, L. et al. Selectively-replicating adenovirus targeting deregulated E2F activity are potent antitumor agents. Cancer Cell 1, 325-337 (2002).
13. Jakubczak, J. et al. An oncolytic adenovirus selective for retinoblastoma protein-defective tumors. Cancer Res. 63, 1490-1499 (2003).
14. Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147-6155 (2000).
15. Ramachandra, M. et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat. Biotechnol. 19, 1035-1041 (2001).
16. Kirn, D. Clinical research results with d/1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8, 89-98 (2001).
17. DeWeese, T. et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472 (2001).
18. Nemunaitis, J. et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kDa gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366 (2000).
19. Nemunaitis, J. et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-298 (2001).
20. Vasey, P., Shulman, L., Gore, M., Kirn, D. & Kaye, S. Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma. J. Clin. Oncol. 20, 1562-1569 (2002).
21. Wold, W.S., Hermiston, T.W. & Tollefson, A.E. Adenovirus proteins that subvert host defenses. Trends Microbiol. 2, 437-443 (1994).
22. Sparer, T.E. et al. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J. Virol. 70, 2431-2439 (1996).
23. Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563 (1997).
24. Heise, C., Williams, A., Xue, S., Propst, M. & Kirn, D. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623-2628 (1999).
25. Heise, C., Williams, A., Olesch, J. & Kirn, D. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 6, 499-504 (1999).
26. Ginsberg, H.S. et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 88, 1651-1655 (1991).
27. Wold, W.S., Tollefson, A.E. & Hermiston, T.W. E3 transcription unit of adenovirus. Curr. Top. Microbiol. Immunol. 199, 237-274 (1995).
28. Dimitrov, T. et al. Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J. Virol. 71, 2830-2837 (1997).
29. Hermiston, T.W., Tripp, R.A., Sparer, T., Gooding, L.R. & Wold, W.S. Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67, 5289-5298 (1993).
30. Lichtenstein, D.L., Krajcsi, P., Esteban, D.J., Tollefson, A.E. & Wold, W.S. Adenovirus RIDβ subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis. J. Virol. 76, 11329-11342 (2002).
31. Gooding, L.R. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect. Agents Dis. 3, 106-115 (1994).
32. Shisler, J., Duerksen, H.P., Hermiston, T.M., Wold, W.S. & Gooding, L.R. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J. Virol. 70, 68-77 (1996).
33. Duncan, S. et al. Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40, 45-61 (1978).
34. Ganly, I., Mauntner, V. & Balmain, A. Productive replication of human adenoviruses in mouse epidermal cells. J. Virol. 74, 2895-2899 (2000).
35. Hayder, H. et al. Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF or lymphotoxin. J. Immunol. 163, 1516-1520 (1999).
36. Efrat, S. et al. Adenovirus early region 3(E3) immunomodulatory genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes 50, 980-984 (2001).
37. Tufariello, J., Cho, S. & Horwitz, M.S. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J. Virol. 68, 453-462 (1994).
38. Schowalter, D.B., Tubb, J.C., Liu, M., Wilson, C.B. & Kay, M.A. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Ther. 4, 351-360 (1997).
39. Liu, Z.X., Govindarajan, S., Okamoto, S. & Dennert, G. Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice. Hepatology31, 665-673 (2000).
40. Krajcsi, P. et al. The adenovirus E3-14.7K protein and the E3-10.4K/14. 5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J. Virol. 70, 4904-4913 (1996).
41. Gooding, L.R. et al. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J. Virol. 65, 4114-4123 (1991).
42. Hailden, G. et al. Novel immunocompetent models for assessment of oncolytic adenovirus. Molecular Therapy 8, 412-424 (2003).
43. Duncan, S. et al. Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40, 45-61 (1978).
44. Wold, W.S., Hermiston, T.W. & Tollefson, A.E. Adenovirus proteins that subvert host defenses. Trends Microbiol. 2, 437-443 (1994).
45. Hayder, H. et al. Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF or lymphotoxin. J. Immunol. 163, 1516-1520 (1999).
46. Krajcsi, P. et al. The adenovirus E3-14.7K protein and the E3-10.4K/14. 5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J. Virol. 70, 4904-4913 (1996).
47. Hermiston, T.W., Tripp, R.A., Sparer, T., Gooding, L.R. & Wold, W.S. Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67, 5289-5298 (1993).
48. Reid, T. et al. Intra-arterial administration of a replication-selective adenovirus (d/1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8, 1618-1626 (2001).
49. Day, D.B., Zachariades, N.A. & Gooding, L.R. Cytolysis of adenovirus-infected murine fibroblasts by IFN-γ-primed macrophages is TNF- and contact-dependent. Cell Immunol. 157, 223-238 (1994).
50. Hermiston, T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest. 105, 1169-1175 (2000).
51. Khuri, F. et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885 (2000).
52. Nagtegaal, I. et al. Local and distant recurrences in rectal cancer patients predicted by the immune response; a histopathological and immunohistochemical study. BMC Cancer 1, 7-11 (2001).